Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern Myanmar
Status:
Withdrawn
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Emerging resistance to artemisinins and their partner drugs severely threatens the treatment
of falciparum malaria in Myanmar with artemisinin combination therapies. To inform drug
policy, it is crucial to evaluate alternative antimalarial treatments.
The investigators here propose a randomized clinical trial comparing parasite clearance
parameters and efficacy of 3 days arterolane-piperaquine with standard treatment with 3 days
dihydroartemisinin (DHA)-piperaquine in adult patients with uncomplicated falciparum malaria
in Myanmar stratified for the presence of "K13" mutation in the infecting parasite strains.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Oxford
Collaborators:
Department of Medical Research, Lower Myanmar Mahidol Oxford Tropical Medicine Research Unit